Notícias

RapAdmin

A Perspective in Science argues that the postmenopausal ovary, long dismissed as a spent organ, stays biologically active for decades. It continues to secrete hormones, mainly testosterone, and in mice, monkeys, and some human samples it accumulates immune cells and senescent stromal cells with a secretory profile. The authors propose that the aged ovary could feed whole-body “inflammaging” in older women.

For most of medical history, the ovary after menopause has been treated as leftover tissue. Textbooks have called it senile, a shriveled husk. Michael Stout of the Oklahoma Medical Research Foundation and Francesca Duncan of Northwestern University and the Buck Institute argue that this picture is wrong, and that the error matters because women now spend roughly a third of their lives after menopause.

The ovary does change at menopause. It loses its follicles, shrinks by about 30 percent, and becomes dominated by stroma, the connective tissue scaffold, along with fibrosis and thickened blood vessels. But it does not go silent. Blood sampled directly from the ovarian vein shows the postmenopausal ovary still releases testosterone, plus smaller amounts of androstenedione, estradiol, estrone, and progesterone. Its stromal cells still carry receptors for the pituitary hormones LH and FSH, and still respond to them.

The newer and more provocative claim concerns inflammation. In mice past reproductive age, the ovary fills progressively with T cells, macrophages, and multinucleated giant cells, and its gene activity shifts from reproductive programs toward immune activation. In aging monkeys, spatial mapping finds inflammatory pockets in the stroma that look like sources of senescence signals. In women aged 50 to 75, a proteomic study still at the preprint stage reports that older ovaries express more proteins tied to complement activation, senescence, and tissue remodeling. When postmenopausal human ovarian tissue is exposed in culture to doxorubicin, a drug that induces senescence, its secretions resemble those of naturally aged ovaries.

Put together, the authors suggest the old ovary may behave something like fat tissue, which was once considered inert storage and is now recognized as an endocrine organ that shapes disease risk. If the ovary leaks inflammatory factors into the circulation, it could contribute to cardiovascular disease, neurodegeneration, muscle loss, and metabolic dysfunction.

The authors do not oversell this. They state that the idea is “only inferential.” One human cell atlas found few immune cells and few senescence markers in the postmenopausal ovary, contradicting the other datasets. Nobody has shown that ovary-derived inflammatory molecules reach meaningful concentrations in blood.

The obvious follow-up question is whether removing the ovaries after menopause would help. Here the evidence is thin and indirect. Removing ovaries before menopause clearly harms health, raising cardiovascular and all-cause mortality, but that reflects sudden hormone loss in younger women. A 2005 modeling study concluded that keeping the ovaries improved survival up to about age 65. A 2022 update found no survival penalty from removing them at hysterectomy at age 50 or later. No penalty is not the same as a benefit, and the authors caution that ovarian androgens still support bone, libido, and metabolism.

The piece is a research agenda, not a result. Its value lies in the question it puts on the table.

Actionable Insights

The practical messages are about decisions women already face.

First, timing dominates. In the Nurses’ Health Study, 16.8 percent of women whose ovaries were removed at hysterectomy died over 28 years, against 13.3 percent who kept them. That is a 3.5 percentage point gap, and after adjusting for other risk factors, a 13 percent higher death rate. Among women under 50 who never took estrogen, the death rate was 41 percent higher, roughly one extra death for every eight surgeries over 35 years.

Second, estrogen therapy appears to offset most of that harm in younger women. In the 2022 model, 52.8 percent of women who lost their ovaries before 50 without estrogen survived to 80, against 63.5 percent who kept them, an 11-point gap that disappeared with estrogen use.

Third, at 50 or older the modeled difference is negligible: 66.9 percent versus 66.4 percent surviving to 80. That is half a percentage point, well inside the margin of error.

Fourth, nothing here supports removing healthy ovaries to reduce inflammation.

Context and Source

  • Paywalled Paper: “Does the postmenopausal ovary still matter?”
  • Institutions: Oklahoma Medical Research Foundation and Oklahoma City VA Medical Center; Feinberg School of Medicine, Northwestern University; Buck Institute for Research on Aging
  • Country: USA
  • Journal: Science, 1 October 2026.
  • Impact evaluation: The impact score of this journal is 45.8, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

RapAdmin

Researchers at Soochow University put 18-month-old male mice through eight weeks of moderate treadmill running, then injected them with bacterial endotoxin (LPS) to trigger brain inflammation. Sedentary mice given LPS performed worse on a spatial memory test and showed more hippocampal inflammation, oxidative damage, and cell-death signaling, along with weaker mitochondrial respiration. Mice that had exercised beforehand performed about as well as uninjected controls, and their hippocampal mitochondria looked healthier on nearly every marker measured.

Older adults often come out of an infection mentally foggier than they went in. A new mouse study asks whether being physically fit beforehand can blunt that hit, and whether mitochondria are part of the explanation.

The team took 32 male mice aged 18 months, old by mouse standards, and split them into four groups of eight. Two groups ran on a treadmill for 40 minutes a day, five days a week, for eight weeks. Two stayed sedentary. A day after the final session, one sedentary group and one trained group received a single injection of lipopolysaccharide, a bacterial cell-wall component that provokes a strong inflammatory response. Three hours later, all mice began six days of testing in the Morris water maze, where they must remember the location of a hidden platform.

Sedentary mice given LPS did poorly. On the final memory test they spent about 27 percent of their time in the correct quadrant of the pool, which is close to what random swimming would produce, compared with about 37 percent for untreated controls. Trained mice given the same injection scored about 38 percent, the same as healthy controls.

The hippocampus, the brain region central to this kind of memory, showed the same pattern. In sedentary LPS mice, inflammatory proteins rose and microglia, the brain’s immune cells, shifted into their activated shape. Markers of oxidative damage and programmed cell death went up, while levels of BDNF, a protein that supports learning, fell by roughly 40 percent. Prior exercise prevented most of these changes.

The authors then looked at mitochondria. Using high-resolution respirometry, they found that hippocampal tissue from sedentary LPS mice had about 30 percent lower maximal respiratory capacity. In trained mice the capacity was preserved, and in fact sat slightly above control levels. Protein markers suggested that exercise also kept the cell’s cleanup machinery (autophagy) running, kept the energy sensor AMPK active, and held the balance between mitochondrial fission and fusion steady.

The authors’ big idea is that mitochondrial fitness acts as a buffer. A brain whose mitochondria are in good order may absorb an inflammatory challenge without tipping into a self-reinforcing loop of oxidative stress, inflammation, and cell death.

That idea is plausible but not shown here. The study never tests whether the mitochondrial changes cause the memory protection. Nobody blocked autophagy or AMPK to see whether the benefit disappeared. Everything was measured at one time point, about eight days after the injection, in whole tissue that mixes neurons, microglia, and astrocytes. Most molecular results come from three animals per group.

There are other constraints. All the exercise happened before the insult, so this is evidence about resilience, not recovery. The mice were all male. The treadmill running was forced. And the claim to be “the first evidence” of this effect is hard to square with earlier work in aged rats showing that wheel running protected against infection-induced memory loss.

So the result adds mechanistic detail to a familiar message. Regular aerobic exercise appears to leave the aging brain better equipped to ride out an inflammatory episode, and healthier mitochondria travel with that protection. Whether they drive it is still an open question.

Actionable Insights

The practical message is one you have heard before: build an aerobic base before you need it. In this study the exercise was done before the inflammatory insult, so the finding concerns preparedness, not rescue once illness strikes.

The dose was modest: 40 minutes of moderate effort, five days a week, for eight weeks. That is 200 minutes weekly, close to standard human guidelines of 150 to 300 minutes.

How big was the effect? Sedentary mice given endotoxin spent about 27 percent of their time searching in the right place, versus 37 percent for healthy controls. Exercised mice given endotoxin scored about 38 percent. In plain terms, the deficit was fully erased. Expressed as a standardized effect size (Cohen’s d, which counts how many “typical spreads” separate two groups), the benefit was roughly 2 to 3. Anything above 0.8 is conventionally called large.

Do not expect that in people. Tiny, uniform groups of lab mice routinely produce inflated effect sizes. Human trials of exercise for cognition in adults over 50 report benefits near 0.3, which is real but small.

Context/Source

RapAdmin

This narrative review argues that postbiotics (killed microbes and their components) could slow cognitive decline by acting along the gut-brain axis. The proposed chain runs from a tighter gut barrier to less inflammatory leakage into the blood, a sturdier blood-brain barrier, calmer microglia, healthier mitochondria and better-preserved synapses. The supporting evidence is seven rodent studies, all in males, plus cell-culture work. The review tabulates no human trials, and the authors themselves conclude that postbiotics are experimental and unproven for cognitive impairment.

Probiotics have a problem: they are alive. Live bacteria must survive manufacturing, shelf storage and stomach acid, and they carry a small infection risk in frail people. Postbiotics sidestep this. They are preparations of heat-killed microbes or their fragments which, according to a new review in Ageing Research Reviews, may still send useful signals to the body after death.

The review, from a team at ISF College of Pharmacy in Punjab, India, asks whether those signals reach the brain. The authors lay out a relay. Dead bacterial cell walls and associated molecules interact with immune receptors in the gut lining. This may tighten the junctions between gut cells and reduce the leakage of bacterial toxins such as lipopolysaccharide into the bloodstream. With fewer inflammatory signals circulating, the blood-brain barrier holds up better, the brain’s immune cells stay calmer, mitochondria produce less oxidative damage, and synapses keep working.

It is a tidy story, and each link has some laboratory support. In rats given a chemical cocktail that mimics aspects of Alzheimer’s disease, heat-killed Bifidobacterium animalis improved maze performance and reduced amyloid build-up over 13 weeks. In mice bred to age quickly, Lacticaseibacillus paracasei improved memory and raised hippocampal dopamine and serotonin. A heat-treated Limosilactobacillus fermentum product protected mice from drug-induced amnesia.

The weakness is the size and quality of that evidence base. The review tabulates seven animal studies. Every one used male rodents. None of the group sizes or the magnitude of benefit are reported in the review, only the direction of change. The models rely on chemical injury or accelerated-aging strains that have a poor record of predicting which treatments work in human dementia. No human trial data are presented.

There is also a definitional tangle. The authors adopt the official consensus definition, under which purified metabolites such as butyrate are not postbiotics. Yet most of the molecular detail in the review, from histone deacetylase inhibition to free fatty acid receptor signaling, comes from studies of exactly those purified short-chain fatty acids. The mechanism described and the product being promoted are not the same thing.

The big idea is plausible and worth testing, since a stable, non-living oral product that reduces gut-derived inflammation would be attractive for older adults. For now, the claim that it protects human cognition is a hypothesis built on rodent mazes.

Actionable Insights

There is no validated human dose, product or protocol in this paper. Anyone buying a “postbiotic for brain health” is running a personal experiment.

Effect size: none can be calculated. The review reports only the direction of results (for example, “improved spatial memory”) without group means, variability or sample sizes. In plain terms, we know the treated animals did better, but not whether they did 5 percent better or 50 percent better. The human effect size is currently unknown, and the default assumption should be zero until trials say otherwise.

Practical points:

  • Animal doses were roughly 100 million to 1 billion killed cells per kilogram or per day, for 2 to 18 weeks. These do not translate reliably to human doses.
  • The best-supported mechanism in the paper involves short-chain fatty acids, which your own gut bacteria make from dietary fiber. Eating adequate fiber and fermented foods is a lower-cost way to act on the same biology, although it is also unproven for cognition.
  • Heat-killed bacterial products are probably low risk for healthy adults, but long-term safety data in cognitively impaired people do not exist.
  • Postbiotics are not a substitute for prescribed dementia medications.
  • Strain matters. Results from one strain cannot be assumed for another.

Context/Source

RapAdmin

A new systematic review in Gut Microbes pulls together 91 studies on how molecules made by gut bacteria affect mitochondria. It covers ten classes of compounds, from butyrate and urolithin A to uremic toxins and bacterial endotoxin. The authors conclude that these chemically unrelated molecules act on the same few control points: the electron transport chain, oxidative stress handling, the creation of new mitochondria, and the removal of damaged ones. Only four compounds (butyrate, propionate, indoxyl sulfate and lipopolysaccharide) earned a “moderate” certainty rating, and that rating describes the direction of a lab effect, not a health benefit. Nearly all the evidence is from cells and rodents, often at doses far above what circulates in human blood.

The idea that gut microbes shape human health has been attached to almost every disease. This review asks a narrower question: when a bacterial product reaches a human cell, what does it do to the mitochondria?

Richard Frye and Daniel Rossignol searched three databases through March 2026 and screened 1,412 records down to 91 studies. They sorted the evidence into ten classes: short-chain fatty acids, secondary bile acids, tryptophan derivatives, uremic toxins and TMAO, hydrogen sulfide, lipopolysaccharide, B vitamins, polyphenol metabolites such as urolithin A, D-lactate, and polyamines such as spermidine.

Their big idea is convergence. Molecules that have nothing in common chemically keep landing on the same mitochondrial machinery. A regulator called PGC-1alpha, which controls the building of new mitochondria, appears again and again. Helpful compounds such as butyrate tend to switch it on. Harmful ones such as indoxyl sulfate, which accumulates in kidney disease, tend to shut it down.

The second theme is dose. Many of these molecules help at low concentrations and harm at high ones. Hydrogen sulfide feeds electrons into the respiratory chain below roughly 20 micromolar and blocks it, cyanide-style, above that. Propionate is a useful fuel at normal levels and jams mitochondrial metabolism when it builds up. Indole-3-propionic acid, often promoted as a beneficial metabolite, raised cellular respiration by about a fifth at a low dose and cut it by a similar amount at a high one.

The reviewers are unusually frank about the weakness of the evidence. Fifty-seven of the 91 studies used cultured cells and 28 used animals. They count only seven as human studies, and most of those measured gene activity or blood markers, not mitochondrial function. No compound achieved a “high” certainty rating. Four reached “moderate”: butyrate (generally beneficial), propionate (harmful at high doses), indoxyl sulfate (harmful) and lipopolysaccharide (mostly harmful).

Urolithin A, which is marketed on the strength of its ability to trigger mitophagy, was rated “low”. The mitophagy evidence comes from worms, mice and muscle cells. The human trial showed safety and shifts in blood and gene markers, but it never measured mitophagy itself.

The concentration problem may matter most. Butyrate experiments typically use 1 to 10 millimolar, which is realistic for the inside of the colon. Human blood contains less than 1 micromolar. Spermidine studies use doses up to 1,000 times normal plasma levels. A cell in the heart or brain never sees what a cell in a dish is given.

The result is a map of plausible mechanisms. The authors say so directly, calling the findings hypothesis-generating and the proposed therapies speculative.

Actionable Insights

Nothing in this paper proves that changing a gut metabolite improves human health or lifespan. With that stated, the practical reading is as follows.

  • Fiber: Fermentable fiber is the best-supported lever, because it feeds butyrate production where butyrate acts, in the colon. Colon cells from germ-free mice had 56 percent less ATP, and butyrate restored energy production to about 70 percent of normal. That is a large effect, but it is in mouse gut cells.
  • Butyrate pills: Oral butyrate is unlikely to reproduce the lab findings elsewhere in the body. Blood levels sit under 1 micromolar, more than 1,000 times below test doses.
  • Urolithin A: Only 30 to 40 percent of people make it from pomegranate, berries or walnuts. Supplements changed blood markers within 28 days, but no human study has confirmed mitophagy.
  • Nicotinamide riboside: A dose of 1,000 mg per day raised muscle mitochondrial DNA in a twin study, but only four twin pairs were compared against placebo.
  • Kidney function: Indoxyl sulfate ran 10 to 21 times higher in dialysis and end-stage patients and tracked with weaker muscle. Protecting kidney function matters more than any supplement here.

No standardized effect sizes (such as Cohen’s d) can be calculated, because the review reports no group means or variability.

Context and Source

RapAdmin

Researchers at Imperial College London gave 28 healthy, psychedelic-naive adults a 1 mg placebo dose of psilocybin, followed four weeks later by a 25 mg dose, with EEG during dosing and MRI before and one month after each session. The high dose sharply increased the irregularity (“entropy”) of brain electrical activity for several hours, and the size of that increase predicted next-day psychological insight and one-month gains in well-being. At one month, participants reported moderately higher well-being and showed modestly better cognitive flexibility. Diffusion MRI found a small decrease in axial diffusivity in prefrontal-subcortical white matter, which the authors tentatively interpret as possible structural plasticity. Functional MRI, the stated primary outcome, was largely null.

A single high dose of psilocybin leaves healthy first-time users feeling measurably better a month later, but the search for a matching lasting signature in the brain has come up largely empty. That is the mixed verdict from an imaging study by the Imperial College London psychedelic research group.

The team gave 28 healthy adults, none of whom had ever taken a psychedelic, two capsules four weeks apart. The first held 1 mg of psilocybin, a dose too small to feel. The second held 25 mg, the dose used in depression trials. Volunteers were told only that each capsule could contain anything up to 25 mg. Brain scans were taken before either dose and a month after each, and brain electrical activity was recorded with EEG during the sessions.

The big idea under test was the “entropic brain” hypothesis: that psychedelics work by making brain activity less predictable, and that this temporary loosening is what allows lasting psychological change. On this point the study delivers its clearest result. Within an hour of the 25 mg dose, the EEG signal became markedly more irregular. The people whose brain activity became most irregular reported the most psychological insight the next day and the largest gains in well-being a month on. Statistically, insight appeared to sit in the middle of that chain, as though the altered brain state produced the insight and the insight produced the improvement.

The lasting changes were harder to pin down. Functional MRI, which the authors name as their primary outcome, produced effects they describe as largely weak and non-significant. A measure of how compartmentalized the brain’s networks are, which fell after psilocybin in earlier depression trials, did not differ significantly from placebo here.

The headline-friendly finding is structural. Diffusion imaging showed a small drop in a measure called axial diffusivity in the white-matter tracts linking the prefrontal cortex to the striatum and thalamus. The authors cautiously float this as possible evidence of anatomical neuroplasticity in humans. They also concede that the same signal turns up in axonal injury and in aging, and that their scanning method cannot tell these apart. A second, standard analysis of the same data found nothing.

On the psychological side, well-being rose by about five points on a 56-point scale, and volunteers made fewer errors on a task that tests the ability to abandon an outdated rule.

The caveats are substantial. Every participant got the placebo first and the real dose second, so the effects of time, practice and repeat scanning are tangled up with the drug. All but one called the 25 mg session the most unusual state of consciousness of their life, so blinding was nominal. The analysis plan was not pre-registered, and dozens of comparisons were run on a sample of about 25.

What survives is one well-supported claim and one tentative one. The acute scrambling of brain activity is real and tracks later benefit. Whether one trip physically remodels a healthy human brain remains unanswered.

Actionable Insights

This paper is a mechanistic study in healthy volunteers, not a test of a health intervention, and it measured no aging outcome.

What it does show, in practical terms:

  • Well-being rose 4.7 points more after 25 mg than after placebo at one month, on a scale running from 14 to 70. The UK population average is 51 with a spread (standard deviation) of 9, so this is about half a standard deviation, a moderate effect (Cohen’s d of 0.6). The uncertainty range runs from 0.1 to 9.3 points, so the true benefit could be trivial or large.
  • Cognitive flexibility improved by about 6 percentage points fewer errors on rule-shift trials (d of 0.5), with an uncertainty range that touches zero.
  • The white-matter change was tiny in absolute terms and its meaning is unknown. It should not be read as “brain rejuvenation.”

Context matters. Dosing occurred under medical screening, with psychological preparation, supervision and music. Psilocybin remains a controlled substance in most jurisdictions. The study followed people for one month only and reports no adverse event data in the main text.

Context/Source

  • Open Access Paper: Human brain changes after first psilocybin use
  • Institution: Centre for Psychedelic Research, Imperial College London (lead site and sponsor); corresponding author now at University of California San Francisco
  • Country: United Kingdom (data collection), with co-authors in the USA, Australia and Canada
  • Journal: Nature Communications, volume 17, article 3977, published 5 May 2026
  • Impact Evaluation: The impact score of this journal is 18.1 (Journal Impact Factor, 2025 JCR data year, released June 2026), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

Researchers at Sun Yat-sen University report that Bacteroides uniformis, a common gut bacterium depleted in people with cardiovascular disease, protects mice against atherosclerosis by secreting pentadecanoic acid (PA, or C15:0), a 15-carbon saturated fatty acid. PA directly inhibits HMG-CoA reductase, the same enzyme targeted by statins, though roughly 300 times more weakly. Blocking the enzyme lowers cholesterol inside liver cells, which triggers the SREBP2 feedback circuit, raises LDL receptor levels, and clears LDL cholesterol from blood. Plaque burden in treated mice fell by roughly a third to a half. The protection disappeared entirely in mice lacking the liver LDL receptor. In 209 human stool and 211 serum samples, PA was significantly lower in people with dyslipidemia.

For a decade, pentadecanoic acid has had one job in nutrition science: it was the molecule you measured in someone’s blood to estimate how much dairy fat they ate. Because cows and other ruminants make it and humans were assumed not to, C15:0 in serum was treated as a reasonably objective dietary biomarker, more trustworthy than a food questionnaire. Epidemiologists used it to show, repeatedly and somewhat awkwardly for dietary guidelines, that people with more dairy fat in their blood had less cardiovascular disease.

The big idea in this paper is that the biomarker was never purely dietary. Gut bacteria make it too, in quantities large enough to matter, and the molecule itself appears to do the work.

The team started from human metagenomes, comparing 223 patients with atherosclerotic cardiovascular disease against 189 healthy controls, and found Bacteroides species depleted in the patients. Feeding live B. uniformis to atherosclerosis-prone mice cut plaque and dropped LDL cholesterol. Heat-killed bacteria did nothing, which pointed to a secreted molecule rather than a structural component of the cell. So they grew 27 liters of the bacterium, split the broth across solvents, and tracked LDL uptake in liver cells through round after round of fractionation until 51.6 milligrams of a single pure compound remained. Mass spectrometry and NMR identified it as PA.

Then comes the part that makes the story mechanistic rather than correlative. Purified human HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, binds PA directly. Three independent methods agree on the affinity, landing between 6 and 7 micromolar. Enzyme kinetics show the fatty acid competes with the natural substrate for the same site. Giving PA alone to mice reproduced most of the bacterium’s benefit. Deleting either of two bacterial genes needed to make PA stripped most of the protection away. And knocking out the LDL receptor in mouse liver abolished it completely, which ties the whole chain together: bacterium makes fatty acid, fatty acid blocks the enzyme, liver senses the cholesterol shortfall, liver puts out more LDL receptors, LDL leaves the blood.

Screening 100 gut strains showed PA production is largely confined to the Bacteroidota phylum, and the biosynthetic genes turn up across more than 4,700 reference genomes. In the authors’ own clinical samples, people with dyslipidemia had less PA in both stool and serum.

The honest reading is that this reframes an epidemiological puzzle rather than solving a clinical problem. If much of the C15:0 in blood is microbial rather than dietary, then twenty years of dairy-fat biomarker studies have been partly measuring the microbiome. That is a real contribution. Whether swallowing C15:0 does anything useful in a human artery is a separate question this paper does not answer.

Actionable Insights

The effect sizes here are large but they are mouse effect sizes, and the human data are observational.

In mice given PA alone, aortic plaque fell 57 percent by one measure and 32 percent by another in the same animals. Cohen’s d was 1.87 and 1.36. A d of 1.0 means the average treated animal does better than about 84 percent of controls, so these are strong effects, but the groups still overlap visibly.

The human numbers are far more modest. Across quartiles of serum C15:0 in a 4,150-person Swedish cohort, moving from the bottom quarter to the top quarter tracks with LDL cholesterol lower by 0.3 mmol/L (about 12 mg/dL, a 7.5 percent relative difference) and cardiovascular disease prevalence lower by 2 percentage points, from 10 percent to 8 percent. That is an absolute risk difference implying roughly 50 people would need the higher level for one fewer case, if the association were causal, which is not established. The pooled hazard ratio across 18 studies was 0.75 (95 percent CI 0.61 to 0.93).

Practically: the amount of C15:0 separating the top and bottom quartiles of the population is about 0.09 percent of total fatty acids, a difference achievable through ordinary full-fat dairy intake. Nothing here demonstrates that supplementing beyond that does more, but is something people can try, and then track their results to see if it does help them lower cholesterol (they did not test effects on LP(a)).

Context and Source

  • Paywalled Paper: A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice.
  • Institution: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, Zhongshan School of Medicine, Sun Yat-sen University (Shenzhen Campus), with the Shenzhen Institute of Advanced Technology (Chinese Academy of Sciences), Shenzhen Bay Laboratory, and the Seventh Affiliated Hospital of Sun Yat-sen University.
  • Country: China.
  • Journal: Nature. Published online 07 October 2026.
  • Impact evaluation: The impact score of this journal is 56.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

RapAdmin

This review fundamentally challenges the prevailing consensus that age-related nicotinamide adenine dinucleotide (NAD) decline is a simple global deficiency. Instead, the authors model NAD as a compartmentalized, high-turnover metabolic circuit where altered flux creates distinct “attractor states” that govern tissue trajectories. Driven by intense consumption from enzymes like CD38 and PARPs, alongside inflammatory extracellular signaling via eNAMPT, these circuits lock aged and injured tissues into chronic fibrosis or malignant transformation rather than regenerative repair.

The prevailing biohacking paradigm treats NAD as a single reservoir that passively drains with age, suggesting that oral precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) simply refill the tank. This paper dismantles that model. The authors demonstrate that NAD operates as a highly compartmentalized circuit split across nuclear, cytosolic, and mitochondrial domains. In aged or diseased states, low intracellular NAD is rarely a primary synthetic defect; it is a compensatory response to overwhelming metabolic demand from DNA repair enzymes (PARP1) and calcium-signaling hydrolases (CD38).

The most critical conceptual shift is the decoupling of intracellular from extracellular NAD signaling. Inside the cell, upregulation of the salvage enzyme NAMPT (iNAMPT) is an adaptive survival mechanism that sustains mitochondrial oxidative phosphorylation. Outside the cell, secreted eNAMPT acts independently of its enzymatic function as a danger-associated molecular pattern (DAMP). By agonizing Toll-like receptor 4 (TLR4), eNAMPT drives severe inflammation and endothelial dysfunction. Therefore, simply flooding the system with NAD precursors while leaving extracellular inflammatory cascades active is metabolically inefficient and potentially dangerous.

The review identifies a transient “pro-repair NAD window” occurring immediately after acute injury. If intracellular NAD turnover is maintained during this window, tissues can regenerate. However, if PARP and CD38 hyperactivation plunge NAD below a critical threshold, the tissue collapses into a “fibrotic attractor state”. Once this scar-dominant environment is established, sustained systemic NAD elevation may inadvertently stabilize the very myofibroblasts driving the pathology, or worse, feed the metabolic resilience of emerging tumors.

Actionable Insights

  • Prophylactic Timing is Critical: In acute injury models, taking NAD precursors proactively yields vastly superior tissue protection compared to reactive dosing. Specifically, NMN administered 30 minutes prior to a cardiac ischemic event resulted in a 44% absolute reduction in tissue necrosis, whereas administration delayed until the reperfusion phase only yielded a 29% reduction.
  • Delayed Central Nervous System Penetration: Biohackers targeting neuroprotection must adjust their time horizons. While human trials show 3000 mg/day of NR achieves a massive 500% relative increase (5-fold) in circulating blood NAD within weeks, translating this into the brain is painfully slow. Detectable increases in cerebral NAD metabolites require at least four continuous weeks of high-dose oral supplementation.
  • Restrict NAD in Active Oncology: Systemic NAD boosting in the presence of active malignancies, particularly tumors with high NAMPT expression, provides metabolic buffering that supports tumor survival and DNA repair against chemotherapeutics.
  • Modulate Consumption Over Supply: In states of chronic inflammation, repairing the “leak” is more vital than turning up the tap. Strategies targeting CD38 inhibition or eNAMPT neutralization will likely yield higher therapeutic efficacy for established fibrosis than isolated precursor loading.

Context/Source

  • Paywalled Paper: NAD circuits in aging, tissue repair and fibrosis, Published 2026 Aug 17.
  • Institution: Tulane University School of Medicine
  • Country: USA
  • Journal Name: Ageing Research Reviews
  • Impact Evaluation: The impact score of this journal is 15.5, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.

RapAdmin

A narrative review in Ageing Research Reviews argues that mitochondrial failure is an early driver of Alzheimer’s, Parkinson’s and Huntington’s disease, not a late side effect. It describes a three-stage decline (metabolic, functional, structural) that ends with leaked mitochondrial DNA fueling brain inflammation. It then surveys hydrogen sulfide donors, sulforaphane, resveratrol, elamipretide, exercise, ketogenic diets and fasting, and recommends combining lifestyle measures with targeted drugs.

For decades, the hunt for the cause of Alzheimer’s, Parkinson’s and Huntington’s disease has centered on the sticky proteins that pile up in dying brains. A new review in Ageing Research Reviews argues that the field has been studying the wreckage. The trouble, the authors say, starts earlier, inside the mitochondria that supply neurons with energy.

Neurons are among the hungriest cells in the body. They burn large amounts of ATP to fire signals and maintain connections, and they are not replaced once lost. The review, from a team led by Zhiguo Wang at the General Hospital of Northern Theater Command in Shenyang, China, lays out a three-stage model of decline. First come metabolic faults: energy output drops and reactive oxygen species rise. Next, the cleanup system for worn-out mitochondria, known as mitophagy, begins to stall, and damaged organelles accumulate. Finally the mitochondria swell, fragment and leak their own DNA into the cell, where immune sensors treat it as a sign of infection and trigger chronic inflammation. That inflammation damages more mitochondria, and the loop feeds itself.

Each disease enters this loop through a different door. In Alzheimer’s, amyloid and tau disrupt the respiratory chain, with complex IV repeatedly implicated. In Parkinson’s, the weak point is complex I, along with inherited faults in the PINK1 and Parkin genes that govern mitophagy. In Huntington’s, the mutant huntingtin protein interferes with mitochondrial transport and calcium handling.

The second half of the paper surveys possible treatments: hydrogen sulfide donors, the plant compounds sulforaphane and resveratrol, the cardiolipin-binding peptide elamipretide, exercise, ketogenic diets and fasting. The authors conclude that the best approach will pair lifestyle measures for broad metabolic support with drugs aimed at specific defects.

That conclusion deserves caution. This is a narrative review, not a systematic one. Across 15 pages it reports no effect size from any human trial in a neurodegenerative disease. Much of the supporting evidence comes from mice and cultured cells. The claim that mitochondrial failure comes first rests largely on animal models and on snapshots of human tissue, which cannot show which event came first. The review itself concedes that the toxic proteins damage mitochondria in turn, so the direction of cause is hard to pin down.

Some of the therapeutic optimism also outruns the trial record. Elamipretide, as the authors acknowledge, failed one Phase 3 trial in mitochondrial muscle disease (though passed another clinical trial), and the review cites no trial of it in Alzheimer’s, Parkinson’s or Huntington’s. Two other results go unmentioned. High-dose coenzyme Q10 showed no benefit in a 600-person Parkinson’s trial. A year-long resveratrol trial in Alzheimer’s patients found faster brain shrinkage in the treated group.

The mitochondrial hypothesis remains a serious and productive idea. This review mostly shows how far it still sits from a proven therapy.

Actionable Insights

Exercise is the only intervention here with solid human data. A pooled analysis of 353 studies (5,973 people) found training raises muscle mitochondrial content by about 23 to 27 percent, with sprint intervals roughly 3.9 times more time-efficient than steady endurance work. That is muscle, not brain.

For brain outcomes the picture is mixed. In a 130-person Parkinson’s trial, home cycling three times weekly for six months held motor worsening to 1.3 points versus 5.6 with stretching. That 4.2-point gap on a 132-point scale is a small to moderate effect. In mild cognitive impairment, a 296-person trial found aerobic exercise no better than stretching. Observational studies link physical activity to about 20 percent lower dementia risk, which cannot prove cause.

One 26-person, 12-week ketogenic diet trial in Alzheimer’s showed a 3.1-point gain in daily function on a scale that runs to 78, a moderate effect, with no significant change in cognition.

The practical reading is to train consistently, include some high-intensity work, and treat everything else as still unproven.

Context and Source

  • Paywalled Paper: Mitochondrial dysfunction in neurodegenerative diseases: Mechanisms and therapeutic advances
  • Institutions: Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang (corresponding); Shenzhen Institute for Advanced Study, University of Electronic Science and Technology of China; Department of Hepatobiliary Surgery, Hainan Provincial People’s Hospital; Department of Biological Science, Jining Medical University.
  • Country: China
  • Journal: Ageing Research Reviews, volume 122 (2026), article 103312, online 20 August 2026.
  • Impact evaluation: The impact score of this journal is 12.4, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

RapAdmin

This systematic literature review and meta correlation evaluated the relationship between systemic inflammation and two distinct dimensions of fatigue in older adults. Analyzing data from 4962 human participants, the researchers found that elevated circulating levels of Interleukin 6 consistently predict both a subjective feeling of exhaustion and an objective decline in muscle endurance. Other common inflammatory markers, such as C reactive protein and Tumor Necrosis Factor alpha, did not show the same consistent statistical relationship with vitality loss.

The aging process is characterized by a gradual decline in intrinsic capacity. A core component of this physiological decline is vitality capacity, which is typically measured through two highly intertwined symptoms: how tired a person feels, and how quickly their muscles fail under stress. Clinical medicine frequently dismisses these symptoms as unavoidable consequences of getting older. However, a growing body of evidence points toward a specific biological driver. Chronic, low grade inflammation is now recognized as a primary catalyst for physical and mental decline. This phenomenon is commonly referred to in the literature as inflammaging.

A new systematic review analyzed data from thousands of older adults to understand exactly which inflammatory markers track closest with vitality loss. Researchers aggregated 27 distinct studies covering 4962 participants. They looked at both subjective questionnaires of self perceived fatigue and objective physical tests of muscle fatigability. The goal was to see if circulating cytokines like Interleukin 6, Tumor Necrosis Factor alpha, and C reactive protein consistently predict fatigue.

The findings establish a clear hierarchy among inflammatory markers. Interleukin 6 emerged as the only cytokine with a statistically significant and consistent correlation across both subjective and objective measures of fatigue. When Interleukin 6 levels rise in the bloodstream, older adults both report feeling more exhausted and demonstrate reduced muscle endurance during grip work. The data showed a distinct negative correlation between Interleukin 6 and muscle fatigue resistance.

Conversely, the data did not support the same conclusions for other well known markers. Tumor Necrosis Factor alpha showed no statistically significant relationship with muscle fatigability. C reactive protein, which is commonly used in general practice to track systemic inflammation, yielded highly mixed results. The correlation between C reactive protein and objective muscle performance was not significant, and its relationship with subjective fatigue was plagued by severe data heterogeneity.

This distinction is biologically coherent. C reactive protein is an acute phase protein produced downstream in the liver. Tumor Necrosis Factor alpha regulates localized tissue inflammation but is notoriously difficult to measure accurately in systemic circulation due to complex spatial and temporal regulation. Interleukin 6 is a direct systemic messenger. It acts as a primary component of the senescence associated secretory phenotype.

The big idea here is that fatigue in older age is a measurable phenotype linked to a specific circulating cytokine. By isolating Interleukin 6 as the dominant signal for vitality loss, this research provides a precise molecular target for biological interventions. It moves the conversation away from vague anti inflammatory advice and directs attention toward specific pathways that drive Interleukin 6 production.

Actionable Insights

For individuals actively working to optimize healthspan, the primary takeaway is the necessity of tracking the correct biomarkers. Standard physicals often measure C reactive protein (CRP) to gauge baseline inflammation. This paper demonstrates that Interleukin 6 is a far superior metric for predicting vitality capacity and muscular endurance in older age. If you are experiencing unexplained fatigue or a drop in physical stamina, tracking and targeting Interleukin 6 is more biologically relevant than relying solely on C reactive protein.

However, you must temper expectations regarding the magnitude of this effect. The meta correlation yielded an r value of 0.189 for muscle fatigability and 0.160 for self perceived fatigue. When converted to standardized effect sizes, this equals a Cohen’s d of approximately 0.38 and 0.32, respectively. These represent small to medium clinical effects. In practical terms, calculating the explained variance reveals that circulating Interleukin 6 levels account for only 3.6 percent of the variance in objective muscle endurance and 2.6 percent of the variance in subjective fatigue. Lowering Interleukin 6 will not single handedly reverse aging or restore youthful energy. It offers a statistically robust but marginal gain, representing just one isolated variable of the broader longevity equation.

Context/Source

Leitura Relacionada:

RapAdmin

A meta-analysis of 87 randomized trials (about 6,500 adults) in the European Heart Journal finds that eating more whole grains improves several heart-disease risk markers, but by small amounts. Per three daily servings, LDL cholesterol fell 0.07 mmol/L, systolic blood pressure 0.8 mmHg and body weight 0.2 kg. Benefits peaked at 60 to 100 g of dry whole grain a day (four to six servings). At that intake, LDL cholesterol, systolic pressure and C-reactive protein crossed the authors’ thresholds for clinical importance.

Whole grains have one of the best reputations in nutrition. Large population studies that follow people for decades link about three servings a day to roughly a fifth fewer heart attacks and cardiovascular deaths. The weakness of that evidence is that people who eat oats and brown rice also tend to exercise, avoid smoking and see their doctors. A new analysis in the European Heart Journal asks a harder question. When people are randomly assigned to eat more whole grains, what happens to the measurements that drive heart disease?

The team, led from Tabriz University of Medical Sciences in Iran with collaborators at Imperial College London, pooled 87 randomized trials involving about 6,500 adults. Unlike earlier reviews, they did not simply compare whole-grain eaters with controls. They modeled the dose, asking how much each risk factor shifted per 48 g of dry whole grain a day, which is about three servings.

The answer is that whole grains work, but modestly. Three servings a day lowered LDL cholesterol by 0.07 mmol/L (about 3 mg/dL), systolic blood pressure by under 1 mmHg, body weight by 200 g and waist size by 2 mm. The authors compared each result with a preset threshold for the smallest change that matters to a patient. Most outcomes fell short. Weight, waist size, fasting glucose, HbA1c and the inflammatory marker interleukin-6 were all rated clinically irrelevant.

That changes how the abstract should be read. It reports reductions in weight, waist size and interleukin-6 “with high certainty.” In the grading system used, this means the authors are highly certain the effects are close to the reported small size. It does not mean a meaningful benefit is well established.

The more useful result comes from the dose curve. Benefits did not rise in a straight line. They appeared at 30 to 40 g a day and peaked at 60 to 100 g of dry whole grain, equal to four to six servings. At about 80 g, LDL cholesterol fell 0.16 mmol/L (6 mg/dL). At 60 g, systolic pressure dropped 2.4 mmHg and C-reactive protein fell 0.58 mg/L. These peak values crossed the thresholds for clinical importance. Beyond roughly 100 g the curves flattened or drifted back toward zero, though few trials tested such high intakes.

There is a gap the paper cannot close. Using standard conversions from drug trials, cholesterol and blood pressure changes of this size predict roughly 3 to 9 percent fewer cardiovascular events. Population studies report about 20 percent. The authors suggest benefits may accumulate over decades or add up across several pathways. A less comfortable explanation is that the population studies overstate the effect because whole-grain eaters are healthier in other ways. The trials offer little support for the accumulation idea. Those running 16 weeks or longer showed smaller effects, not larger ones.

Grain type matters too. Oats showed the strongest cholesterol lowering, consistent with their soluble fiber, while rye was linked to lower adiposity. The authors rated those subgroup findings as low credibility.

The practical message is that swapping refined grains for whole grains is a low-risk move that nudges several risk factors in the right direction. It is not a substitute for treating high cholesterol or high blood pressure.

Actionable Insights

The trials point to a target of 60 to 100 g of dry whole grain a day, which is four to six servings. A bowl of oatmeal made from 40 g of dry oats plus two slices of 100 percent whole-grain bread comes to roughly 70 to 80 g. Eating more than that showed no clear added benefit.

At that intake, LDL cholesterol falls by about 6 mg/dL (0.16 mmol/L), roughly 4 to 5 percent for a typical adult. Systolic blood pressure falls by about 2.4 mmHg, roughly 2 percent. For comparison, a moderate-dose statin lowers LDL by 30 percent or more, and a single blood pressure drug lowers systolic pressure by about 9 mmHg. Whole grains deliver around a tenth of the first and a quarter of the second.

If both changes held for years, standard conversions predict about 9 percent fewer heart attacks and strokes. For someone with a 10 percent ten-year risk, that is under 1 percentage point.

Do not expect weight loss (0.5 kg on average) or better blood sugar (HbA1c down 0.05 points). Choose oats or barley if cholesterol is the goal, and replace refined grains instead of adding calories.

Context/Source

  • Open Access Paper: Whole-grain consumption and cardiometabolic risk: a meta-analysis of randomized trials
  • Institutions: Tabriz University of Medical Sciences (lead and funder), Imperial College London, University of Western Ontario, Norwegian Institute of Public Health, Oslo New University College
  • Countries: Iran (lead), United Kingdom, Canada, Norway
  • Journal: European Heart Journal (Oxford University Press, for the European Society of Cardiology)
  • Impact evaluation: The impact score of this journal is 45.6, evaluated against a typical high-end range of 0 to 60+ for top general medical and science journals, therefore this is an Elite impact journal.